Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ4 | P56696 | 3/20 | 0.31 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25032353 | 1.00 | KCNQ4 (0.31) | KCNQ4KCNQ5PDE4APDE4BPDE4C | |
| SCHEMBL30832661 | 0.86 | LPAR1 (0.34) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31304808 | 0.86 | ACHE (0.35) | KCNQ4KCNQ5 | |
| SCHEMBL30832717 | 0.84 | KCNQ4 (0.33) | KCNQ4KCNQ5 | |
| SCHEMBL30184603 | 0.80 | KCNQ4 (0.33) | KCNQ4KCNQ5 | |
| SCHEMBL25033082 | 0.80 | KCNQ4 (0.33) | KCNQ4KCNQ5 | |
| SCHEMBL31270395 | 0.79 | POLQ (0.35) | KCNQ4KCNQ5 | |
| SCHEMBL25033081 | 0.79 | KCNQ4 (0.35) | KCNQ4KCNQ5 | |
| SCHEMBL30832688 | 0.79 | KCNQ4 (0.35) | KCNQ4KCNQ5 | |
| SCHEMBL29184902 | 0.71 | KEAP1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | KCNQ4 4825/4885KCNQ5 4796/4885PDE4A 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.